Imatinib mesylate for the treatment of pulmonary arterial hypertension

Expert Opinion on Investigational Drugs

Volumn 21, Issue 1, 2012, Pages 119-134

  Freyhaus, Henrik Ten ^a   Dumitrescu, Daniel ^a   Berghausen, Eva ^a   Vantler, Marius ^a   Caglayan, Evren ^a   Rosenkranz, Stephan ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Imatinib mesylate; Platelet derived growth factor; Pulmonary arterial hypertension; Receptor tyrosine kinase; Tyrosine kinase inhibitor

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; ENDOTHELIN 1; ENDOTHELIN RECEPTOR ANTAGONIST; IMATINIB; NITRIC OXIDE; PHOSPHODIESTERASE V INHIBITOR; PLATELET DERIVED GROWTH FACTOR A; PLATELET DERIVED GROWTH FACTOR B; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; SEROTONIN; VASODILATOR AGENT;

AIRWAY REMODELING; ANTIHYPERTENSIVE THERAPY; ARTICLE; CATHETER COMPLICATION; CATHETER INFECTION; CELL PROLIFERATION; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; FLUSHING; HOMEOSTASIS; HUMAN; HYPOXIA; INJECTION SITE PAIN; LIVER TOXICITY; LUNG VASCULAR RESISTANCE; NAUSEA; NONHUMAN; PALLIATIVE THERAPY; PATHOGENESIS; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR BINDING; REGULATORY MECHANISM; SEPSIS; SIDE EFFECT; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; UPREGULATION; VASCULAR ENDOTHELIUM; VASOCONSTRICTION; VASODILATATION;

ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; HUMANS; HYPERTENSION, PULMONARY; MUSCLE, SMOOTH, VASCULAR; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; TIME FACTORS; TREATMENT OUTCOME;

EID: 84555190301     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2012.632408     Document Type: Article

References (129)

1. Badesch DB, Champion HC, Sanchez MA, et al. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2009;54(Suppl S):55-66
2. McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol 2009;53:1573-619
3. Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009;30:2493-537
4. Rosenkranz S. Pulmonary hypertension: current diagnosis and treatment. Clin Res Cardiol 2007;96:527-41 (Pubitemid 47106497)
5. Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009;54(Suppl S):S43-54
6. Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med 2004;351:1655-65
7. Van Wolferen SA, Marcus JT, Boonstra A, et al. Prognostic value of right ventricular mass, volume, and function in idiopathic pulmonary arterial hypertension. Eur Heart J 2007;28:1250-7 (Pubitemid 47343830)
8. Haworth SG. The cell and molecular biology of right ventricular dysfunction in pulmonary hypertension. Eur Heart J 2007;28(Suppl H):H10-16
9. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Ann Intern Med 1991;115:343-9
10. Benza RL, Miller DP, Gomberg-Maitland M, et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 2010;122:164-72
11. Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010;122:156-63
12. Schermuly RT, Dony E, Ghofrani HA, et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 2005;115:2811-21 (Pubitemid 41434408)
13. Perros F, Montani D, Dorfmuller P, et al. Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2008;178:81-8 (Pubitemid 351919196)
14. Hassoun PM, Mouthon L, Barbera JA, et al. Inflammation, growth factors, and pulmonary vascular remodeling. J Am Coll Cardiol 2009;54(Suppl S):S10-19
15. Morrell NW, Adnot S, Archer SL, et al. Cellular and molecular basis of pulmonary arterial hypertension. J Am Coll Cardiol 2009;54(Suppl S):S20-31
16. Galie N, Palazzini M, Manes A. Pulmonary arterial hypertension: from the kingdom of the near-dead to multiple clinical trial meta-analyses. Eur Heart J 2010;31:2080-6
17. Newman JH, Trembath RC, Morse JA, et al. Genetic basis of pulmonary arterial hypertension: current understanding and future directions. J Am Coll Cardiol 2004;43(Suppl S):33S-39S (Pubitemid 38759715)
18. Machado R, Eickelberg O, Elliott CG, et al. Genetics and genomics of pulmonary arterial hypertension. J Am Coll Cardiol 2009;54(Suppl S):S32-42
19. Tuder RM, Abman SH, Braun T, et al. Development and pathology of pulmonary hypertension. J Am Coll Cardiol 2009;54(Suppl S):S3-9
20. Stenmark KR, Gerasimovskaya E, Nemenoff RA, Das M. Hypoxic activation of adventitial fibroblasts: role in vascular remodeling. Chest 2002;122(Suppl 6):326S-334S (Pubitemid 36043023)
21. Tuder RM, Voelkel N. Pulmonary hypertension and inflammation. J Lab Clin Med 2010;132:16-24
22. Barst RJ, Gibbs SR, Ghofrani HA, et al. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 2009;54(Suppl S):S78-84
23. Badesch DB, Abman SH, Simonneau G, et al. Medical therapy for pulmonary arterial hypertension. Updated ACCP evidence-based clinical practice guidelines. Chest 2007;131:1917-28 (Pubitemid 46981654)
24. Sitbon O, Humbert M, Jais X, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005;111:3105-11 (Pubitemid 40847788)
25. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996;334:296-302
26. Galie N, Brundage BH, Ghofrani HA, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009;119:2894-903
27. Galie N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005;353:2148-57 (Pubitemid 41653106)
28. Olschewski H, Simonneau G, Galié N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002;347:322-9 (Pubitemid 34815354)
29. Oudiz RJ, Galie N, Olschewski H, et al. Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension. J Am Coll Cardiol 2009;54:1971-81
30. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903 (Pubitemid 34984638)
31. Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002;165:800-4 (Pubitemid 34229650)
32. Humbert M, Segal ES, Kiely DG, et al. Results of European post-marketing surveillance of bosentan in pulmonary hypertension. Eur Respir J 2007;30:338-40
33. Simmoneau G, Rubin LJ, Galie N, et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med 2008;149:521-30
34. Chockalingam A, Gnanavelu G, Venkatesan S, et al. Efficacy and optimal dose of sildenafil in primary pulmonary hypertension. Int J Cardiol 2005;99:91-5 (Pubitemid 40261030)
35. Galie N, Manes A, Negro L, et al. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J 2009;30:394-403
36. Chen SJ, Chen YF, Meng QC, et al. Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats. J Appl Physiol 1995;79:2122-31
37. Falcetti E, Hall SM, Phillips PG, et al. Smooth muscle proliferation and role of the prostacyclin (IP) receptor in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2010;182:1161-70
38. Wharton J, Davie N, Upton PD, et al. Prostacyclin analogues differentially inhibit growth of distal and proximal human pulmonary artery smooth muscle cells. Circulation 2000;102:3130-6
39. Wharton J, Strange JW, M€oller GM, et al. Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. Am J Respir Crit Care Med 2005;172:105-13 (Pubitemid 40923321)
40. Haga M, Yamashita A, Paszkowiak J, et al. Oscillatory shear stress increases smooth muscle cell proliferation and Akt phosphorylation. J Vasc Surg 2003;37:1277-84 (Pubitemid 41123106)
41. Sterpetti AV, Cucina A, Santoro L, et al. Modulation of arterial smooth muscle cell growth by haemodynamic forces. Eur J Vasc Surg 1992;6:16-20
42. Raines EW. PDGF and cardiovascular disease. Cytokine Growth Factor Rev 2004;15:237-54 (Pubitemid 38781049)
43. Grimminger F, Schermuly RT. PDGF receptor and its antagonists: role in treatment of PAH. Adv Exp Med Biol 2010;661:435-46
44. Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 1999;79:1283-316 (Pubitemid 29473317)
45. Kazlauskas A. Receptor tyrosine kinases and their targets. Curr Opin Genet Dev 1994;4:5-14 (Pubitemid 24060290)
46. Rosenkranz S, Kazlauskas A. Evidence for distinct signaling properties and biological responses induced by the PDGF receptor alpha and beta subtypes. Growth Factors 1999;16:201-16 (Pubitemid 129725725)
47. Schwartz SM. Perspectives series: cell adhesion in vascular biology: smooth muscle migration in atherosclerosis and restenosis. J Clin Invest 1997;99:2814-16
48. Ten Freyhaus H, Huntgeburth M, Wingler K, et al. Novel Nox inhibitor VAS2870 attenuates PDGF-dependent smooth muscle cell chemotaxis, but not proliferation. Cardiovasc Res 2006;71:331-41
49. Tanizawa S, Ueda M, van der Loos CM, et al. Expression of platelet derived growth factor B chain and beta receptor in human coronary arteries after percutaneous transluminal coronary angioplasty: an immunohistochemical study. Heart 1996;75:549-56 (Pubitemid 26225022)
50. Abe J, Deguchi J, Takuwa Y, et al. Tyrosine phosphorylation of platelet derived growth factor beta receptors in coronary artery lesions: implications for vascular remodelling after directional coronary atherectomy and unstable angina pectoris. Heart 1998;79:400-6 (Pubitemid 28197759)
51. Levitzki A. PDGF receptor kinase inhibitors for the treatment of restenosis. Cardiovasc Res 2005;65:581-6 (Pubitemid 40142661)
52. Caglayan E, Vantler M, Leppanen O, et al. Disruption of PDGF-dependent PI 3-kinase and PLCgamma activity abolishes vascular smooth muscle cell proliferation and migration and attenuates neointima formation in vivo. J Am Coll Cardiol 2011;57:2527-38
53. Arcot SS, Lipke DW, Gillespie MN, Olson JW. Alterations of growth factor transcripts in rat lungs during development of monocrotaline-induced pulmonary hypertension. Biochem Pharmacol 1993;46:1086-91 (Pubitemid 23280552)
54. Cai Y, Han M, Luo L, et al. Increased expression of pdgf and c-myc genes in lungs and pulmonary arteries of pulmonary hypertensive rats induced by hypoxia. Chin Med Sci J 1996;11:152-6
55. Huang Q, Sun R. Changes of PDGF-alpha and beta receptor gene expression in hypoxic rat pulmonary vessels. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 1997;19:470-3
56. Katayose D, Ohe M, Yamauchi K, et al. Increased expression of PDGF-alpha and beta-chain genes in rat lungs with hypoxic pulmonary hypertension. Am J Physiol 1993;264:L100-6 (Pubitemid 23079462)
57. Kwapiszewska G, Wilhelm J, Wolff S, et al. Expression profiling of laser-microdissected intrapulmonary arteries in hypoxia-induced pulmonary hypertension. Respir Res 2005;6:109
58. Jones R, Capen D, Jacobson M, Munn L. PDGF and microvessel wall remodeling in adult rat lung: imaging PDGF-aa and PDGF-ralpha molecules in progenitor smooth muscle cells developing in experimental pulmonary hypertension. Cell Tissue Res 2006;326:759-69 (Pubitemid 44786375)
59. Humbert M, Monti G, Fartoukh M, et al. Platelet-derived growth factor expression in primary pulmonary hypertension: Comparison of HIV seropositive and HIV seronegative patients. Eur Respir J 1998;11:554-9 (Pubitemid 28194842)
60. Lanner MC, Raper M, Pratt WM, et al. Heterotrimeric G proteins and the platelet-derived growth factor receptor-beta contribute to hypoxic proliferation of smooth muscle cells. Am J Respir Cell Mol Biol 2005;33:412-19 (Pubitemid 41416293)
61. Balasubramaniam V, Le Cras TD, Ivy DD, et al. Role of platelet-derived growth factor in vascular remodeling during pulmonary hypertension in the ovine fetus. Am J Physiol Lung Cell Mol Physiol 2003;284:L826-33 (Pubitemid 36459029)
62. Bergsten E, Uutela M, Li X, et al. PDGF-D is a specific, protease-activated ligand for the PDGF beta-receptor. Nat Cell Biol 2001;3:512-16 (Pubitemid 32422089)
63. Gilbertson DG, Duff ME, West JW, et al. Platelet-derived growth factor C (PDGF-C), a novel growth factor that binds to PDGF alpha and beta receptor. J Biol Chem 2001;276:27406-14
64. LaRochelle WJ, Jeffers M, McDonald WF, et al. PDGF-D, a new protease-activated growth factor. Nat Cell Biol 2001;3:517-21 (Pubitemid 32422090)
65. Li X, Ponten A, Aase K, et al. PDGF-C is a new protease-activated ligand for the PDGF alpha-receptor. Nat Cell Biol 2000;2:302-9
66. Leveen P, Pekny M, Gebre-Medhin S, et al. Mice deficient for PDGF B show renal, cardiovascular, and hematological abnormalities. Genes Dev 1994;8:1875-87 (Pubitemid 24273888)
67. Lindahl P, Johansson BR, Leveen P, Betsholtz C. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 1997;277:242-5 (Pubitemid 27446080)
68. Mellgren AM, Smith CL, Olsen GS, et al. Platelet-derived growth factor receptor beta signaling is required for efficient epicardial cell migration and development of two distinct coronary vascular smooth muscle cell populations. Circ Res 2008;103:1393-401
69. Soriano P. Abnormal kidney development and haematological disorders in PDGF beta-receptor mutant mice. Genes Dev 1994;8:1888-96
70. Tallquist MD, Klinghoffer RA, Heuchel R, et al. Retention of PDGFR-beta function in mice in the absence of phosphatidylinositol 3́-kinase and phospholipase Cgamma signalling pathways. Genes Dev 2000;14:3179-90 (Pubitemid 32015135)
71. Tallquist MD, Soriano P, Klinghoffer RA. Growth factor signaling pathways in vascular development. Oncogene 1999;18:7917-32 (Pubitemid 30066237)
72. Baumer AT, Ten Freyhaus H, Sauer H, et al. PI3 kinase-dependent membrane recruitment of rac-1 and p47phox is critical for alpha PDGF receptor-induced production of reactive oxygen species. J Biol Chem 2008;283:7864-76
73. Chung J, Grammer TC, Lemon KP, et al. PDGF-and insulin-dependent pp70S6K activation mediated by phosphatidylinositol-3-OH-kinase. Nature 1994;370:71-5
74. DeMali KA, Whiteford CC, Ulug ET, Kazlauskas A. Platelet-derived growth factor-dependent cellular transformation requires either phospholipase Cgamma or phosphatidylinositol 3 kinase. J Biol Chem 1997;272:9011-18 (Pubitemid 27154901)
75. Fambrough D, McClure K, Kazlauskas A, Lander ES. Diverse signaling pathways activated by growth factor receptors induce broadly overlapping, rather than independent, sets of genes. Cell 1999;97:727-41 (Pubitemid 29278047)
76. Joly M, Kazlauskas A, Fay FS, Corvera S. Disruption of PDGF receptor trafficking by mutation of its PI-3 kinase sites. Science 1994;263:684-7 (Pubitemid 24076296)
77. Klinghoffer RA, Duckworth B, Valius M, et al. Platelet-derived growth factor-dependent activation of phosphatidylinositol 3-kinase is regulated by receptor binding of SH2-domain-containing proteins which influence Ras activity. Mol Cell Biol 1996;16:5905-14 (Pubitemid 26315112)
78. Kundra V, Escobedo JA, Kazlauskas A, et al. Regulation of chemotaxis by the platelet-derived growth factor receptor beta. Nature 1994;367:474-6 (Pubitemid 24046051)
79. Montmayeur JP, Valius M, Vandenheede J, Kazlauskas A. The platelet-derived growth factor beta-receptor triggers multiple cytoplasmic signaling cascades that arrive at the nucleus at distinguishable inputs. J Biol Chem 1997;272:32670-8
80. Rosenkranz S, DeMali KA, Gelderloos JA, et al. Identification of the receptor-associated signaling enzymes that are required for platelet-derived growth factor-AA-dependent chemotaxis and DNA synthesis. J Biol Chem 1999;274:28335-43
81. Valius M, Kazlauskas A. Phospholipase C-gamma1 and phosphatidylinositol 3 kinase are the downstream mediators of the PDGF receptor's mitogenic signal. Cell 1993;73:321-34 (Pubitemid 23123310)
82. Valius M, Secrist J-P, Kazlauskas A. The GTPase activating protein of Ras suppresses platelet-derived growth factor beta receptor signaling by silencing phospholipase C-gamma1. Mol Cell Biol 1995;15:3058-71
83. Ten Freyhaus H, Dagnell M, Leuchs M, et al. Hypoxia enhances platelet-derived growth factor signaling in the pulmonary vasculature by down-regulation of protein tyrosine phosphatases. Am J Respir Crit Care Med 2011;183:1092-102
84. Miyake S, Mullane-Robinson KP, Lill NL, et al. Cbl-mediated negative regulation of platelet-derived growth factor receptor-dependent cell proliferation. A critical role for Cbl tyrosine kinase-binding domain. J Biol Chem 1999;274:16619-28
85. Rosenkranz S, Ikuno Y, Leong FL, et al. Src family kinases negatively regulate platelet-derived growth factor alpha receptor-dependent signaling and disease progression. J Biol Chem 2000;275:9620-7 (Pubitemid 30185194)
86. Kappert K, Paulsson J, Sparwel J, et al. Dynamic changes in the expression of DEP-1 and other PDGF receptor-antagonizing PTPs during onset and termination of neointima formation. FASEB J 2007;21:523-34 (Pubitemid 46213499)
87. Kappert K, Peters KG, Bohmer FD, Ostman A. Tyrosine phosphatases in vessel wall signaling. Cardiovasc Res 2005;65:587-98 (Pubitemid 40138979)
88. Humar R, Kiefer FN, Berns H, et al. Hypoxia enhances vascular cell proliferation and angiogenesis in vitro via rapamycin (mTOR)-dependent signaling. FASEB J 2002;16:771-80 (Pubitemid 34615125)
89. Schultz K, Fanburg BL, Beasley D, et al. Hypoxia and hypoxia-inducible factor-1alpha promote growth factor-induced proliferation of human vascular smooth muscle cells. Am J Physiol 2006;290:H2528-34 (Pubitemid 43846084)
90. Cohen MH, Johnson JR, Pazdur R. US Food and Drug Administration drug approval summary: conversion of imatinib mesylate (sti571; gleevec) tablets from accelerated approval to full approval. Clin Cancer Res 2005;11:12-19 (Pubitemid 40075773)
91. Baselga J. Targeting tyrosine kinases in cancer: the second wave. Science 2006;312:1175-8 (Pubitemid 43801135)
92. Gschwind HP, Pfaar U, Waldmeier F, et al. Metabolism and disposition of imatinib mesylate in healthy volunteers. Drug Metab Dispos 2005;33:1503-12 (Pubitemid 41323999)
93. Le Coutre P, Kreuzer KA, Pursche S, et al. Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588. Cancer Chemother Pharmacol 2004;53:313-23 (Pubitemid 38392356)
94. Peng B, Lloyd P, Schran H, et al. Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 2005;44:879-94 (Pubitemid 41252840)
95. Nakamura K, Akagi S, Ogawa A, et al. Pro-apoptotic effects of imatinib on PDGF-stimulated pulmonary artery smooth muscle cells from patients with idiopathic pulmonary arterial hypertension. Int J Cardiol 2011. [Epub ahead of print]
96. Vantler M, Caglayan E, Zimmermann WH, et al. Systematic evaluation of anti-apoptotic growth factor signaling in vascular smooth muscle cells. Only phosphatidylinositol 3¢-kinase is important. J Biol Chem 2005;280:14168-76 (Pubitemid 40517319)
97. Vantler M, Karikkineth BC, Naito H, et al. PDGF-BB protects cardiomyocytes from apoptosis and improves contractile function of engineered heart tissue. J Mol Cell Cardiol 2010;48:1316-23
98. Sato N, Narita M, Takahashi M, et al. The effects of STI571 on antigen presentation in dendritic cells generated from patients with chronic myelogenous leukemia. Hematol Oncol 2003;2:67-75 (Pubitemid 36717431)
99. Ghofrani HA, Seeger W, Grimminger F. Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med 2005;353:1412-13 (Pubitemid 41362714)
100. Patterson KC, Weissmann A, Ahmadi T, Farber HW. Imatinib mesylate in the treatment of refractory idiopathic pulmonary arterial hypertension. Ann Intern Med 2006;145:152-3 (Pubitemid 46780594)
101. Souza R, Sitbon O, Parent G, et al. Long term imatinib treatment in pulmonary arterial hypertension. Thorax 2006;61:736 (Pubitemid 44211786)
102. ten Freyhaus H, Dumitrescu D, Bovenschulte H, et al. Significant improvement of right ventricular function by imatinib mesylate in scleroderma-associated pulmonary arterial hypertension. Clin Res Cardiol 2009;98:265-7
103. Ghofrani HA, Morrell NW, Hoeper MM, et al. Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am J Respir Crit Care Med 2010;182:1171-7
104. Ghofrani HA, Morrell NW, Hoeper MM, et al. Long term use of imatinib in patients with severe pulmonary arterial hypertension. Am J Respir Crit Care Med 2010;181(Suppl):abstract 2513
105. Hoeper M, Barst RJ, Galie N, et al. Imatinib in pulmonary arterial hypertension, a randomized efficacy study (IMPRES). Eur Respir J 2011;38(Suppl):abstract 413
106. Press release, Novartis, September 26, 2011
107. Druker BJ, Guilhot F, ÓBrian SG, et al. IRIS investigators. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408-17 (Pubitemid 44903745)
108. Tong WG, Kantarjian H, O'Brien S, et al. Imatinib front-line therapy is safe and effective in patients with chronic myelogenous leukemia with pre-existing liver and/or renal dysfunction. Cancer 2010;116:3152-9
109. Kerkela R, Grazette L, Yacobi R, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006;12:908-16 (Pubitemid 44175142)
110. Cheng H, Force T. Molecular mechanisms of cardiovascular toxicity of targeted cancer therapeutics. Circ Res 2010;106:21-34
111. Fernandez A, Sanguino A, Peng Z, et al. An anticancer c-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic. J Clin Invest 2007;117:4044-54 (Pubitemid 350224113)
112. Atallah E, Durand JB, Kantarijan H, Cortes J. Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood 2007;110:1233-7 (Pubitemid 47281421)
113. Dumitrescu D, Seck C, Ten Freyhaus H, et al. Fully reversible pulmonary arterial hypertension associated with dasatinib treatment for chronic myeloid leukemia. Eur Respir J 2011;38:218-20
114. Hennigs JK, Keller G, Baumann HJ, et al. Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension? BMC Pulm Med 2011;11:30
115. Mattei D, Feola M, Orzan F, et al. Reversible dasatinib-induced pulmonary arterial hypertension and right ventricle failure in a previously allografted CML patient. Bone Marrow Transplant 2009;43:967-8
116. Quinta's-Cardama A, Kantarijan H, O'Brien S, et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 2007;25:3908-14 (Pubitemid 47477268)
117. Rasheed W, Flaim B, Seymour JF. Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukemia. Leuk Res 2009;33:861-4
118. Abe K, Toba M, Alzoubi A, et al. Tyrosine kinase inhibitors are potent acute pulmonary vasodilators in rats. Am J Respir Crit Care Med 2011. [Epub ahead of print]
119. Young KC, Torres E, Hehre D, et al. Neonatal c-kit mutant mice exhibit decreased susceptibility to hypoxia-induced pulmonary hypertension. Circulation 2009;120:S750-1
120. Gambaryan N, Perros F, Montani D, et al. Imatinib inhibits bone marrow-derived c-kit+ cell mobilization in hypoxic pulmonary hypertension. Eur Respir J 2010;35:1209-11
121. Dahal BK, Kosanovic D, Kaulen C, et al. Involvement of mast cells in monocrotaline-induced pulmonary hypertension in rats. Respir Res 2011;12:60
122. Sitbon O, Galie N. Treat-to-target strategies in pulmonary arterial hypertension: the importance of using multiple goals. Eur Respir Rev 2010;19:272-8
123. Delgado JF, Conde E, Sanchez V, et al. Pulmonary vascular remodeling in pulmonary hypertension due to chronic heart failure. Eur J Heart Fail 2005;7:1011-16 (Pubitemid 41443595)
124. Ogawa A, Firth AL, Yao W, et al. Inhibition of mTOR attenuates store-operated Ca2+ entry in cells from endarterectomized tissues of patients with chronic thromboembolic pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2009;297:L666-76
125. Baroni SS, Santillo M, Bevilacqua F, et al. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 2006;354:2667-76
126. Dahal BK, Cornitescu T, Tretyn A, et al. Role of epidermal growth factor inhibition in experimental pulmonary hypertension. Am J Respir Crit Care Med 2010;181:158-67
127. Izikki M, Guignabert C, Fadel E, et al. Endothelial-derived FGF2 contributes to the progression of pulmonary hypertension in humans and rodents. J Clin Invest 2009;119:512-23
128. Merklinger SL, Jones PL, Martinez EC, Rabinovitch M. Epidermal growth factor receptor blockade mediates smooth muscle cell apoptosis and improves survival in rats with pulmonary hypertension. Circulation 2005;112:423-31 (Pubitemid 41022085)
129. Berghausen E, Janssen W, Vantler M, et al. The PI 3-kinase isoform p110alpha is essential for growth factor-induced vascular remodeling in pulmonary hypertension. Eur Heart J 2011;32(Suppl):abstract 3072